Literature DB >> 24788556

Radiofrequency ablation of hepatic metastases: factors influencing local tumor progression.

Chang-Hsien Liu1, Chih-Yung Yu, Wei-Chou Chang, Ming-Shen Dai, Cheng-Wen Hsiao, Yu-Ching Chou.   

Abstract

BACKGROUND: Although radiofrequency ablation (RFA) of nonresectable hepatic metastases has gained wide acceptance by showing survival benefit in selected patients, scattered reports are available regarding risk factors of local control of percutaneous RFA. The purpose of this study was to prospectively evaluate the factors influencing local tumor progression after percutaneous RFA of hepatic metastases.
METHODS: Sixty-nine hepatic metastatic lesions in 54 patients were treated by percutaneous RFA. Efficacy was evaluated by contrast-enhanced computed tomography or magnetic resonance imaging at 1 month after ablation, then at 3-month intervals for the first year and biannually thereafter.
RESULTS: The results of the log-rank test showed that tumor size of <3 cm (p = 0.024) and the absence of tumor contiguous with large vessels (p = 0.002) significantly correlated with local control for hepatic metastases. Cox regression analysis showed that the tumor size <3 cm and the absence of tumor contiguous with large vessels were independent factors (p = 0.055 and 0.009, respectively). The results of the log-rank test showed that neither the threshold post-ablation margin of 1.8 cm (p = 0.064) nor the presence of a tumor with subcapsular location (p = 0.134) correlated with the success of local control.
CONCLUSIONS: Percutaneous RFA is more effective in achieving local control in patients with hepatic metastases when the tumor size is <3 cm and not contiguous with large vessels.

Entities:  

Mesh:

Year:  2014        PMID: 24788556     DOI: 10.1245/s10434-014-3738-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  2 in total

1.  Clinical evaluation of in silico planning and real-time simulation of hepatic radiofrequency ablation (ClinicIMPPACT Trial).

Authors:  Michael Moche; Harald Busse; Jurgen J Futterer; Camila A Hinestrosa; Daniel Seider; Philipp Brandmaier; Marina Kolesnik; Sjoerd Jenniskens; Roberto Blanco Sequeiros; Gaber Komar; Mika Pollari; Martin Eibisberger; Horst Rupert Portugaller; Philip Voglreiter; Ronan Flanagan; Panchatcharam Mariappan; Martin Reinhardt
Journal:  Eur Radiol       Date:  2019-08-30       Impact factor: 5.315

2.  Ultrasound-guided radiofrequency ablation enhances natural killer-mediated antitumor immunity against liver cancer.

Authors:  Zelai Mo; Hailan Lu; Shaowei Mo; Xiangmin Fu; Shunwu Chang; Jie Yue
Journal:  Oncol Lett       Date:  2018-03-12       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.